Superior Outcomes With Continuing Tenofovir Versus Switching to Zidovudine in Second-Line Antiretroviral Therapy in Haiti

Samuel Pierre; Iryna Bocharova; Catherine Nguyen; Fabienne Homeus; Gaetane Julmiste; Youry Macius; Vanessa Rouzier; Patrice Severe; Marie Marcelle Deschamps; Colette Guiteau Moise; Clovy Bellot; Johnny Wu; Vanessa R Rivera; Rochelle Sun; Jean W Pape; Bernard Liautaud; Serena P Koenig

doi:10.1093/ofid/ofab559

Superior Outcomes With Continuing Tenofovir Versus Switching to Zidovudine in Second-Line Antiretroviral Therapy in Haiti

Open Forum Infect Dis. 2021 Nov 23;8(12):ofab559. doi: 10.1093/ofid/ofab559. eCollection 2021 Dec.

Authors

Samuel Pierre¹, Iryna Bocharova², Catherine Nguyen², Fabienne Homeus¹, Gaetane Julmiste¹, Youry Macius¹, Vanessa Rouzier^{1

3}, Patrice Severe¹, Marie Marcelle Deschamps¹, Colette Guiteau Moise¹, Clovy Bellot¹, Johnny Wu², Vanessa R Rivera^{1

3}, Rochelle Sun², Jean W Pape^{1

3}, Bernard Liautaud¹, Serena P Koenig⁴

Affiliations

¹ Le Groupe Haïtien d'Etude du Sarcome de Kaposi et des Infections Opportunistes, Port-au-Prince, Haiti.
² Analysis Group, Boston, Massachusetts, USA.
³ Center for Global Health, Department of Medicine, Weill Cornell Medical College, New York, New York, USA.
⁴ Division of Global Health Equity, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Abstract

We compared viral suppression rates between patients who continued tenofovir disoproxil fumarate (TDF)/lamivudine (3TC) vs switched to zidovudine (ZDV)/3TC in combination with a boosted protease inhibitor after failure of first-line efavirenz/TDF/3TC. We found higher rates of viral suppression with continued TDF/3TC compared with switching to ZDV/3TC.

Keywords: HIV; genotypic resistance; second-line therapy; tenofovir disoproxil fumarate; zidovudine.